DUBLIN–(BUSINESS WIRE)–The “Global
and China IGBT Industry Report, 2019-2025” report has been
added to ResearchAndMarkets.com’s offering.
The IGBT industry will boom in the wake of the vigorous development of
NEV, smart gird and rail transit, and is estimated to be worth USD9.421
billion in 2025, growing at a CAGR of 9.4%.
IGBT finds wide application in fields ranging from home appliances and
digital products to aviation & aerospace and high-speed rails, smart
grid and new energy vehicles.
Power semiconductor vendors mostly adopt the IDM model featured with
complete wafer foundries, chip factories, and packaging houses. The
tycoons like Infineon and On-Semi with the IDM model have strong control
ability over cost and quality. The power semiconductor vendors in
Europe, America, and Japan with the IDM model are dedicated to high-end
products. Also, the majority of vendors from Mainland China employ the
IDM model but focus on the low-end diode and low-voltage MOSFET. While
Taiwanese peers take the fabless model and are mostly engaged in chip
fabrication and packaging.
Power semiconductor industry is characterized by high concentration
since the world’s top 10 vendors commanded 62.58% of the market in 2018.
Infineon, the largest player, shared 19.87%. The power semiconductor
market is firmly dominated by European, American and Japanese companies,
where Chinese companies started late with backward technology.
Currently, power semiconductor companies can be grouped into three
echelons: the first is represented by European and American giants such
as Infineon and On-Semi; the second echelon is comprised of Japanese
companies like Mitsubishi and Fuji Electric; the third echelon refers to
Chinese players including Hangzhou Silan Microelectronics and Nexperia,
This report covers the following:
IGBT and power semiconductor industry (definition, application,
production process, technology roadmap, and technical comparison)
IGBT downstream industries (PV power generation, wind power
generation, industrial application, electric vehicle, charging piles,
home appliances, rail transit, etc.)
Global and Chinese IGBT markets (market size, supply & demand,
competition pattern, and development trend)
21 global and Chinese IGBT vendors like Infineon, Fuji Electric,
On-Semi and Mitsubishi (profile, operation, R&D, production bases and
IGBT technology & business).
Key Topics Covered:
1. Overview of IGBT
1.2 Operating Principle
1.3 Evolution of Technology Roadmap
1.4 Main Applications
2. Industry Chain
2.1 PV Market
2.1.2 Demand for IGBT
2.2 Wind Power Market
2.2.2 Demand for IGBT
2.3 Rail Transit
2.4 Industrial Applications
2.5 Electric Vehicle
2.6 Charging Pile
3. Global and China IGBT Market
3.2 Market Size
3.3 Competition Pattern
3.4 Supply Chain
3.5 IGBT Development Trend
4. Chinese IGBT Vendors
4.1 Jilin Sino-Microelectronics
4.1.3 Capacity and Shipment
4.1.4 IGBT Business
4.2 Hua Hong Semiconductor Limited
4.3 Zhuzhou CRRC Times Electric Co, Ltd.
4.5 Jiangsu MacMic Science & Technology
4.6 Keda Semiconductor
4.7 Hangzhou Silan Microelectronics
4.8 CSMC Technologies Corporation
4.9 Advanced Semiconductor Manufacturing Co, Ltd. (ASMC)
4.10 Nanjing Silvermicro Electronics
4.11 Shenzhen Founder Microelectronics
5. Global IGBT Suppliers
5.1 Fuji Electric
5.1.3 IGBT Business
5.1.4 Electric Vehicle IGBT
For more information about this report visit https://www.researchandmarkets.com/r/64ems8
Laura Wood, Senior Press Manager
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
For GMT Office Hours Call +353-1-416-8900
Willow Biosciences Reports Third Quarter 2019 Results and Provides Operations Update
Willow Biosciences Inc. (“Willow” or the “Company“) (CSE: WLLW, OTCQB: CANSF) has released its financial and operating results for the three and nine months ended September 30, 2019.
“Over the past few months, Willow has continued to advance its business strategy and achieved several important milestones,” said Trevor Peters, Willow’s President and Chief Executive Officer. “We have made meaningful progress on advancing our yeast strain performance and fully expect to meet our projected timing of scale-up development in the first half of 2020. In addition, we have completed the commissioning of our three labs and expanded our team of highly skilled scientists, preparing us for future development. As the market for CBD and other cannabinoids continues to develop, Willow is positioned as a leader in delivering ultra-pure, pharmaceutical grade cannabinoids, at a highly competitive cost for the consumer packaged goods and pharmaceutical industries.”
Selected financial and operational information is outlined below and should be read in conjunction with Willow’s unaudited condensed consolidated interim financial statements (“Financial Statements”) and related management’s discussion and analysis (“MD&A”) which are available on SEDAR at www.sedar.com or on the Willow’s website at www.willowbio.com.
Highlights for the Quarter:
- Willow’s science team successfully increased cannabinoid production by 25-fold and identified hundreds of beneficial genetic changes that are expected to provide additional increases.
- Willow ended the quarter with strong liquidity, including approximately $24.0 million of cash on hand at September 30, 2019.
- Willow continued to build out our three labs in Calgary, Alberta, Burnaby, British Columbia and Mountain View, California, spending $3.2 million in capex in the quarter ($6.4 million year to date as of September 30th). With the bulk of our capital spending to set up our labs behind us, Willow continues to focus on advancing our yeast strain to produce ultra-pure, pharmaceutical grade cannabidiol (CBD).
- In the quarter we moved into our new facility in Calgary, Alberta located in the Life Sciences Innovation Hub at the University Research Park. The 4,000 square foot secure facility employs cutting-edge bioassay capabilities, liquid handling robots, and analytical instrumentation, and leverages access to the University of Calgary’s plant cultivation resources and growth chambers.
- Willow continues to progress its intellectual property portfolio and expects to file five new U.S. provisional patent applications and one Patent Cooperation Treaty “PCT” conversion (which will convert an existing provisional patent application to a U.S. PCT application), all prior to the end of 2019.
- Subsequent to the end of the quarter, the Company received its DEA Controlled Substances Registration Certificate for our Mountain View, California facility, which allows the Company to develop yeast strains which produce CBD.
- On November 5, 2019, the Company commenced trading on the OTCQB® Venture Market under the ticker “CANSF”.
- Willow’s directors and officers remain committed to the long-term success of the Company and since July 1, 2019, certain officers and board members of Willow have purchased approximately 1.5 million common shares and warrants of Willow in the market for aggregate proceeds of approximately $840,000.
During the past quarter, we have expanded our research and development team to 33 technical staff, including 21 Ph.D. level scientists, across our three sites. Our multidisciplinary team consists of plant scientists, strain engineers, analytical chemists and fermentation process engineers. The team’s focus has now shifted from expanding its technical capabilities to program execution and operational excellence. Our plant sciences team in Canada continues to advance its understanding of cannabinoid accumulation in C. sativa along with translation of these results in our yeast production host. These results are further complemented by our high-throughput strain engineering capabilities in our San Francisco Bay Area labs to expand upon beneficial genetic diversity and further optimize our yeast strain toward commercial targets. As a result of these combined efforts, we have increased cannabinoid production by 25-fold and identified hundreds of beneficial genetic changes that will provide additional increases. These improved strains are now undergoing evaluation in fermentation tanks at our development partner’s facilities. At our current trajectory, we anticipate delivering a strain for scale up development starting in the first half of 2020.
Willow ended the quarter in a strong financial position, with approximately $23.2 million in working capital and $24.0 million of cash on hand.
The Corporation’s financial results are summarized as follows:
Three months ended
Nine months ended
Balance sheet ($000’s):
Cash and cash equivalents
Weighted average shares outstanding
Basic and diluted (000’s)
Year to date 2019 has been transformative for the Company. The transactions Willow has completed have had a significant impact on the comparability of the Company’s period over period results. See the Financial Statements and MD&A for further details.
Willow will continue to focus on developing and refining our yeast-based strains that biosynthesize CBD, optimizing our production levels and improving the performance of our processes. We expect to reach a scalable production level in the first half of 2020, triggering the initiation of Noramco, Inc.’s efforts to ramp up production, file regulatory submissions and develop marketing and distribution plans. The scaling up of production to commercial levels is expected to take 12 to 18 months, followed by regulatory approval for the manufacturing process and customer sampling during 2021, and first bulk commercial sales anticipated in late 2021 or early 2022.
Following our successful financings, Willow is well positioned to fund our operations to commercialization.
Willow continues to evaluate strategic relationships with various entities in the consumer packaged goods and pharmaceutical industries. These partnerships will look to define our market participation and potentially gain entry into new global markets.
SOURCE Willow Biosciences Inc.
OPSEU gives thumbs down to Ford’s attempt to fix cannabis debacle
The Ford government’s latest reset of its disastrous decision to privatize cannabis sales is bound to make an already bad situation worse, says OPSEU President Warren (Smokey) Thomas.
“What will it take for the government to understand that cannabis retail stores need to be operated by trained professionals?” asked Thomas.
Thomas can’t believe the Ford government is set to move to an “open allocation” system for issuing retail cannabis licenses as early as January that could result in over 1,000 outlets across Ontario.
“I can’t figure out why the Conservatives think it makes sense to continue on with this privatization disaster,” said Thomas. “We need a Responsible Plan, the kind of plan the previous government had that would have put cannabis sales in the hands of the LCBO.
“Polls have shown us that Ontarians are 11 times more likely to trust the LCBO than private retailers when it comes to keeping cannabis out of kids’ hands,” Thomas added.
“This is a matter of public safety. LCBO stores have trained professionals who have the training and experience to handle sales of controlled substances.”
Over a year ago when the discussion around cannabis retail stores began, the Ford government made a number of promises – promises they are now breaking, says Thomas.
“They promised a tightly regulated system. What does this new plan involve? It involves flooding the market. How is that responsible? The second promise was to keep our kids safe. This doesn’t keep our kids safe.”
“Our members who operate LCBO stores are experts in responsible sales,” he adds. “They keep our kids and our communities safe because they are trained and qualified. They take social responsibility seriously.”
It’s time for Ford to give up trying to find solutions for a problem that doesn’t exist, says OPSEU First Vice President/Treasurer, Eduardo (Eddy) Almeida.
“The solution has been there in front of them all along,” says Almeida. “How many failed attempts and half-baked ideas are they going to try?”
“First Mr. Ford hits us with a crazy lottery scheme that resulted in only a handful of stores operated by people as random as the process that selected them and now he just wants to open this up as a free-for-all? We need a clear and thoughtful plan, and the LCBO is the solution.”
SOURCE Ontario Public Service Employees Union (OPSEU)
CannTrust Provides Default Status Report
CannTrust Holdings Inc. (“CannTrust” or the “Company”, TSX: TRST, NYSE: CTST) today is providing a status update in accordance with its obligations under the alternative information guidelines set out in National Policy 12-203 – Management Cease Trade Orders (“NP 12-203”), which require the Company to provide bi-weekly updates until such time as the Company is current with its filing obligations under Canadian securities laws. As previously announced, the Company is subject to a management cease trade order (“MCTO”) issued by the Ontario Securities Commission. The MCTO prohibits the directors and executive officers of the Company from trading in or acquiring securities of the Company until two full business days after the Company files an interim financial report for the three and six month periods ended June 30, 2019, an interim management’s discussion and analysis for the corresponding period and certifications of interim filings. The MCTO does not affect the ability of investors who are not insiders to trade in the securities of the Company.
Timing of Financial Results
Although the Company is continuing to make progress in working with its independent auditor in connection with its restated audited financial statements for the year ended December 31, 2018, its restated interim financial statements for the first quarter of 2019, and its interim financial statements for the second and third quarters of 2019, together with the related management’s discussion and analysis for the corresponding periods, such financial statements are unlikely to be completed and filed before the end of the calendar year.
The Company advises that: (i) other than as disclosed above, there have been no material changes to the information contained in the Company’s August 16, 2019 news release, August 29, 2019 news release, September 12, 2019 news release, September 26, 2019 news release, October 10, 2019 news release, October 24, 2019 news release, and November 7, 2019 news release; (ii) it intends to continue to comply with the alternative information guidelines of NP 12-203; and (iii) except as previously disclosed, there are no subsequent specified defaults (actual or anticipated) within the meaning of NP 12-203.
This press release contains “forward-looking information” within the meaning of Canadian Securities laws and “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and other applicable United States safe harbor laws, and such statements are based upon CannTrust’s current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information and forward-looking statements can be identified by the use of forward-looking terminology such as “believes”, “expect”, “likely”, “may”, “will”, “should”, “intend”, “anticipate”, “potential”, “proposed”, “estimate” and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions “may”, “would” or “will” happen, or by discussions of strategy.
The forward-looking information and statements in this news release include statements relating to the corrective actions being taken by the Company, and Health Canada’s pending determinations. Forward-looking information and statements necessarily involve known and unknown risks, including, without limitation: actions taken in respect of the Company’s products by its customers and regulators; results of Health Canada’s investigation, including orders and compliance measures required by Health Canada and their impact on the operations, inventory, assets and financial condition of the Company; the Company’s implementation of remediation plans and related actions; regulatory approval; risks associated with general economic conditions; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States and elsewhere; the cannabis industry in Canada generally; and, the ability of CannTrust to implement its business strategies.
Any forward-looking information and statements speak only as of the date on which they are made, and, except as required by law, CannTrust does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for CannTrust to predict all such factors. When considering these forward-looking information and statements, readers should keep in mind the risk factors and other cautionary statements in CannTrust’s Annual Information Form dated March 28, 2019 (the “AIF”) and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com and filed as an exhibit CannTrust’s Form 40-F annual report under the United States Securities Exchange Act of 1934, as amended, with the United States Securities and Exchange Commission on EDGAR at www.sec.gov. The risk factors and other factors noted in the AIF could cause actual events or results to differ materially from those described in any forward-looking information or statements.
The TSX and NYSE do not accept responsibility for the adequacy or accuracy of this release.
SOURCE CannTrust Holdings Inc.
Cannabis4 weeks ago
ecxx.com first digital asset exchange to integrate MyInfo for user identity verification
Cannabis3 weeks ago
iAnthus Announces Retirement of Paul Rosen from Board of Directors
Cannabis3 weeks ago
Lithium Iron Phosphate Batteries Market Worth $10.6 Billion by 2024 – Exclusive Report by MarketsandMarkets™
Cannabis2 weeks ago
Supreme Cannabis First Quarter Earnings Release Scheduled for November 14, 2019
Cannabis3 weeks ago
Bridge Farm Group Selects Heliospectra MITRA LED Lighting for United Kingdom Greenhouse and Cultivation of Fresh Herbs and Plants
Cannabis2 weeks ago
Addressing THC Detox Myths and Facts
Cannabis2 weeks ago
Cannabis Can Treat Epileptic Seizures
Cannabis3 weeks ago
Aphria Inc. Doubles Production Capacity After Receiving Cultivation Licence for Aphria Diamond